S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
'Civil War’ continues box-office campaign at No. 1
Lithium Overdose: Can These 2 Lithium Stocks Recover in 2024?
Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Intuitive Surgical Leads the Robotic Surgery Movement
Stock market today: World shares shrug off Wall St blues as investors eye corporate earnings
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
'Civil War’ continues box-office campaign at No. 1
Lithium Overdose: Can These 2 Lithium Stocks Recover in 2024?
Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Intuitive Surgical Leads the Robotic Surgery Movement
Stock market today: World shares shrug off Wall St blues as investors eye corporate earnings
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
'Civil War’ continues box-office campaign at No. 1
Lithium Overdose: Can These 2 Lithium Stocks Recover in 2024?
Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Intuitive Surgical Leads the Robotic Surgery Movement
Stock market today: World shares shrug off Wall St blues as investors eye corporate earnings
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
'Civil War’ continues box-office campaign at No. 1
Lithium Overdose: Can These 2 Lithium Stocks Recover in 2024?
Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Intuitive Surgical Leads the Robotic Surgery Movement
Stock market today: World shares shrug off Wall St blues as investors eye corporate earnings
NASDAQ:CLNN

Clene (CLNN) Stock Price, News & Analysis

$0.35
+0.02 (+5.85%)
(As of 04/19/2024 08:50 PM ET)
Today's Range
$0.31
$0.36
50-Day Range
$0.31
$0.50
52-Week Range
$0.25
$1.09
Volume
1.24 million shs
Average Volume
995,274 shs
Market Capitalization
$44.85 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.50

Clene MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,761.4% Upside
$6.50 Price Target
Short Interest
Healthy
0.13% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.12mentions of Clene in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$8,775 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.33) to ($0.32) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.79 out of 5 stars

Medical Sector

398th out of 908 stocks

Pharmaceutical Preparations Industry

179th out of 421 stocks

CLNN stock logo

About Clene Stock (NASDAQ:CLNN)

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.

CLNN Stock Price History

CLNN Stock News Headlines

Clene's (CLNN) Buy Rating Reaffirmed at HC Wainwright
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
Clene Inc Ordinary Shares
Breaking Down Clene: 4 Analysts Share Their Views
Clene: Q4 Earnings Insights
Clene to Present at the 36th Annual ROTH Conference
CLNN Mar 2024 1.000 put
CLNN Mar 2024 3.000 call
See More Headlines
Receive CLNN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Clene and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/13/2024
Today
4/21/2024
Next Earnings (Estimated)
5/10/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CLNN
Fax
N/A
Employees
82
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$6.50
High Stock Price Target
$10.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+1,761.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-49,500,000.00
Net Margins
-7,569.42%
Pretax Margin
-7,569.42%

Debt

Sales & Book Value

Annual Sales
$650,000.00
Book Value
$0.10 per share

Miscellaneous

Free Float
94,271,000
Market Cap
$44.85 million
Optionable
Optionable
Beta
0.50
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Mr. Robert Etherington MBA (Age 57)
    CEO, President & Director
    Comp: $590.98k
  • Mr. Morgan R. Brown CPA (Age 56)
    M.B.A., Chief Financial Officer
    Comp: $374.05k
  • Mr. Mark G. Mortenson ESQ. (Age 66)
    Chief Science Officer
    Comp: $482.98k
  • Mr. Jerry Miraglia J.D.
    General Counsel & Corporate Secretary
  • Mr. Michael T. Hotchkin
    Chief Development Officer
  • Ms. Mary Anne Mcneil
    Head of Human Resources
  • Dr. Benjamin M. Greenberg M.D.
    M.H.S., Head of Medical

CLNN Stock Analysis - Frequently Asked Questions

Should I buy or sell Clene stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Clene in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CLNN shares.
View CLNN analyst ratings
or view top-rated stocks.

What is Clene's stock price target for 2024?

4 equities research analysts have issued 1-year price targets for Clene's shares. Their CLNN share price targets range from $4.00 to $10.00. On average, they predict the company's share price to reach $6.50 in the next year. This suggests a possible upside of 1,761.4% from the stock's current price.
View analysts price targets for CLNN
or view top-rated stocks among Wall Street analysts.

How have CLNN shares performed in 2024?

Clene's stock was trading at $0.2966 on January 1st, 2024. Since then, CLNN shares have increased by 17.7% and is now trading at $0.3492.
View the best growth stocks for 2024 here
.

Are investors shorting Clene?

Clene saw a decrease in short interest in the month of March. As of March 31st, there was short interest totaling 162,900 shares, a decrease of 37.9% from the March 15th total of 262,500 shares. Based on an average daily volume of 743,600 shares, the days-to-cover ratio is presently 0.2 days.
View Clene's Short Interest
.

When is Clene's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024.
View our CLNN earnings forecast
.

How were Clene's earnings last quarter?

Clene Inc. (NASDAQ:CLNN) issued its quarterly earnings results on Wednesday, March, 13th. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.07) by $0.01. The company had revenue of $0.17 million for the quarter, compared to analyst estimates of $0.14 million. Clene had a negative net margin of 7,569.42% and a negative trailing twelve-month return on equity of 253.48%.

How do I buy shares of Clene?

Shares of CLNN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CLNN) was last updated on 4/22/2024 by MarketBeat.com Staff

From Our Partners